Vol 20, Supp. A (2024)
Case report
Published online: 2024-10-03
A case of a patient treated with targeted therapy in brain metastases of melanoma with BRAF V600 mutation
DOI: 10.5603/ocp.102699
Abstract
The prognosis of patients diagnosed with melanoma with numerous metastatic lesions in the brain is poor, despite the
use of modern techniques of radiotherapy, molecularly targeted therapies and immunotherapy. The author presents
a case report of a 46-year-old patient with disseminated melanoma of the skin, who was diagnosed with
asymptomatic brain metastases in screening tests for the clinical trial. During systemic treatment, binimetinib
with encorafenib and pembrolizumab were used.
Keywords: melanomainhibitor BRAFinhibitor MEKimmunotherapy
References
- Rutkowski P, Kozak K, Świtaj T. Czerniak i inne nowotwory skóry. In: Krzakowski M, Potemski P, Wysocki P. ed. Onkologia kliniczna. Tom II. Via Medica, Gdańsk 2023: 957–961.
- https://onkologia.org.pl/pl/czerniak-skory-leczenie#page-main-image (29.08.2023).
- Charakterystyka Produktu Leczniczego INN-Encorafenib.
- Charakterystyka Produktu Leczniczego INN-binimetinib.